Autolus Therapeutics PLC
NASDAQ:AUTL

Watchlist Manager
Autolus Therapeutics PLC Logo
Autolus Therapeutics PLC
NASDAQ:AUTL
Watchlist
Price: 1.61 USD 1.26% Market Closed
Market Cap: 428.5m USD

Intrinsic Value

The intrinsic value of one AUTL stock under the Base Case scenario is 10.02 USD. Compared to the current market price of 1.61 USD, Autolus Therapeutics PLC is Undervalued by 84%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

AUTL Intrinsic Value
10.02 USD
Undervaluation 84%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Autolus Therapeutics PLC

What is Valuation History?
Ask AI Assistant
What other research platforms think about AUTL?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is AUTL valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Autolus Therapeutics PLC.

Explain Valuation
Compare AUTL to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about AUTL?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Autolus Therapeutics PLC

Current Assets 514.6m
Cash & Short-Term Investments 367.4m
Receivables 91.4m
Other Current Assets 55.8m
Non-Current Assets 147.4m
PP&E 123.5m
Intangibles 20.3m
Other Non-Current Assets 3.6m
Current Liabilities 83.1m
Accounts Payable 11m
Accrued Liabilities 57.1m
Other Current Liabilities 15m
Non-Current Liabilities 313.4m
Long-Term Debt 251.9m
Other Non-Current Liabilities 61.5m
Efficiency

Free Cash Flow Analysis
Autolus Therapeutics PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Autolus Therapeutics PLC

Revenue
51.1m USD
Cost of Revenue
-82.4m USD
Gross Profit
-31.3m USD
Operating Expenses
-242.6m USD
Operating Income
-273.9m USD
Other Expenses
49.1m USD
Net Income
-224.8m USD
Fundamental Scores

AUTL Profitability Score
Profitability Due Diligence

Autolus Therapeutics PLC's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

21/100
Profitability
Score

Autolus Therapeutics PLC's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

AUTL Solvency Score
Solvency Due Diligence

Autolus Therapeutics PLC's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Long-Term Solvency
Low D/E
50/100
Solvency
Score

Autolus Therapeutics PLC's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AUTL Price Targets Summary
Autolus Therapeutics PLC

Wall Street analysts forecast AUTL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AUTL is 9.49 USD with a low forecast of 5.05 USD and a high forecast of 13.65 USD.

Lowest
Price Target
5.05 USD
214% Upside
Average
Price Target
9.49 USD
489% Upside
Highest
Price Target
13.65 USD
748% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Autolus Therapeutics PLC
does not pay dividends
Shareholder Yield

Current shareholder yield for AUTL is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

AUTL News

What is the Intrinsic Value of one AUTL stock?

The intrinsic value of one AUTL stock under the Base Case scenario is 10.02 USD.

Is AUTL stock undervalued or overvalued?

Compared to the current market price of 1.61 USD, Autolus Therapeutics PLC is Undervalued by 84%.

Back to Top